Pharma manufacturing news in brief
pharmafile | August 16, 2011 | News story | Manufacturing and Production |Â Â pharma manufacturing newsÂ
Jubilant announces an $80 million agreement to supply an unnamed product over the next three years, plus there are facility updates from Gilead, GlaxoSmithKline and Osmotica and news of a smallpox contract for Ampac Fine Chemicals.
Contract research and manufacturing services company Jubilant Life Sciences says it has been awarded a long-term, strategic-level outsourcing contract from an undisclosed drug company. The deal is worth around $80 million over the next three years, and could top $100 million if all goes well. The supply agreement is for a product with “huge demand in the market”, according to Jubilant, which says it has already received an advance payment from the customer.
US drugmaker Gilead Sciences says it has resolved all outstanding manufacturing compliance problems at a facility in San Dimas, California, which was the subject of an FDA warning letter in September 2010. The violations at the plant related mainly to the production of Gilead’s injectable antibiotic AmBisome (amphotericin B) liposome for injection, “as well as general observations related to systems, procedures and controls focused on ensuring product quality”.
GlaxoSmithKline has signed an agreement to set up manufacturing capacity in Iraq via a collaboration with local drugmaker Modern Drug Industries that will see GSK brands filled and finished in the capital Baghdad. In time, the drugmaker says it may move ahead with commissioning its own production unit.
Drug delivery specialist Osmotica Pharmaceutical is planning to open an R&D and manufacturing unit in Georgia, USA, which will lead to the creation of 165 jobs over five years. The firm currently uses contract manufacturers for its production needs, but plans to build up its own capacity with the new unit in Marietta, which was formerly owned by Solvay Pharmaceuticals. The company is investing around $20 million on the site, with $2 million coming from state and local incentives.
Ampac Fine Chemicals has won a contract to validate a commercial-scale manufacturing process for a smallpox drug candidate, CMX001, in development at pharmaceutical company Chimerix. The drugmaker is developing the compound under a biodefense grant from the US government. The validation campaign will be conducted in AFC’s recently-completed second semi-works unit, which has been set up in its secure facility in Rancho Cordova, California.
Phil Taylor
Related Content
Pharma manufacturing news in brief
Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates …
Bayer planning joint venture to make drugs in Russia
Germany’s Bayer AG has joined a number of its peers in the pharmaceutical industry with …
Pharma manufacturing news in brief
FDA sets aside $35m for manufacturing research, Anteco, Apicore and Vetter provide facility updates and …
